Hypertension Canada’s 2017 guidelines for diagnosis,risk assessment,prevention and treatment of hypertension in adults for pharmacists: An update

Abstract

Get full access to this article

View all access options for this article.

References

Campbell

Burgess

Choi

BCK

et al . Methods and overview of the Canadian recommendations. CMAJ 1999;160(9 suppl):S1-S6.

Leung

Daskalopoulou

Dasgupta

et al . Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults. Can J Cardiol 2017;33(5):557-76.

Hua

Carter

Bellerive

. Bridging the gap: innovative knowledge translation and the Canadian Hypertension Education Program. Can J Cardiol 2012;8:258-61.

Padwal

Bienek

McAlister

Campbell

. Epidemiology of hypertension in Canada: an update. Can J Cardiol 2016;32:687-94.

McAlister

Wilkins

Joffres

et al . Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011;183:1007-13.

Shiu

Simpson

Johnson

Tsuyuki

. Quantifying opportunities to affect diabetes management in the community. Can Pharm J (Ott) 2006;139(3):37-8.

Chisholm-Burns

Kim Lee

Spivey

et al . US pharmacists’ effect as a team member on patient care: systematic review and meta-analyses. Med Care 2010;48:923-33.

Santschi

Chiolero

Burnand

et al . Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med 2011;171:1441-53.

Santschi

Chiolero

Paradis

et al . Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta analysis of randomized controlled trials. Diabetes Care 2012;35:2706-17.

10.

Santschi

Chiolero

Colosimo

et al . Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000718.

11.

Tsuyuki

Houle

Charrois

et al . A randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation 2015;132:93-100.

12.

Pojskic

Jackson

Malek

Cimino

. Impact of community pharmacist interventions in hypertension management on patient outcomes: a randomized controlled trial. Can Pharm J (Ott) 2014;147:S17.

13.

Tsuyuki

Al Hamarneh

Jones

Hemmelgarn

. Effectiveness of community pharmacist prescribing and care on cardiovascular risk reduction: randomized controlled RxEACH trial. J Am Coll Cardiol 2016;67(24):2846-54.

14.

Houle

SKD

Tsuyuki

Campbell

NRC

. The Canadian Hypertension Education Program (CHEP) 2011 guidelines for pharmacists. Can Pharm J (Ott) 2011;144:295-304.

15.

Padwal

Straus

McAlister

. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ 2001;322(7292):977-80.

16.

Warwick

Falaschetti

Rockwood

et al . No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 2015;13:78.

17.

Williamson

Supiano

Applegate

et al . Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673-82.

18.

Wright

Jr Williamson

Whelton

et al . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.

19.

Xie

Atkins

et al . Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43.

20.

Olde Engberink

Frenkel

van den Bogaard

Brewster

Vogt

van den Born

. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 2015;65:1033-40.

21.

Roush

Ernst

Kostis

Tandon

Sica

. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015;65:1041-6.

22.

Pareek

Messerli

Chandurkar

et al . Efficacy of low-dose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. J Am Coll Cardiol 2016;67:379-89.

23.

Gradman

Parise

Lefebvre

et al . Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013;61:309-18.

24.

Wald

Law

Morris

et al . Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300.

25.

Feldman

Zou

Vandervoort

et al . A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-53.

26.

Jamerson

Weber

Bakris

et al . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.

27.

Lonn

Bosch

Lopez-Jaramillo

et al . Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20.

28.

Sherrill

Halpern

Khan

et al . Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011;13:898-909.

29.

Law

Wald

Morris

Jordan

. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427.

30.

Corrao

Nicotra

Parodi

et al . Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011;58:566-72.

31.

Dasgupta

Quinn

Zarnke

et al . The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014;30:485-501.

32.

Bangalore

Messerli

Wun

et al . J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-908.

33.

Bangalore

Qin

Sloan

et al . What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010;122:2142-51.

34.

Messerli

Mancia

Conti

et al . Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-83.

35.

Rabkin

Shiekh

Wood

. The impact of left ventricular mass on diastolic blood pressure targets for patients with coronary artery disease. Am J Hypertens. 2016;29:1085-93.

36.

Rabkin

. Considerations in understanding the coronary blood flow–left ventricular mass relationship in patients with hypertension. Curr Cardiol Rev. 2017;13:75-83.

37.

Anderson

Heeley

Huang

et al . Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355-65.

38.

Qureshi

Palesch

Barsan

et al . Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-43.

39.

Williams

MacDonald

Morant

et al . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-68.

40.

Calhoun

Jones

Textor

et al . Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-26.

41.

Myat

Redwood

Qureshi

et al . Resistant hypertension. BMJ 2012;345:e7473.

42.

Myers

Kaczorowski

Dawes

Godwin

. Automated office blood pressure measurement in primary care. Can Fam Phys 2014;60:127-32.

43.

Daskalopoulou

Rabi

Zarnke

et al . The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015;31:549-68.

44.

Clement

De Buyzere

De Bacquer

et al . Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-15.

45.

Lawes

CMM

Vander Hoorn

Rodgers

for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-8.

46.

Forouzanfar

Liu

Roth

et al . Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm hg, 1990-2015. JAMA 2017;317(2):165-82.

47.

Gee

Bienek

McAlister

et al . Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol 2012;28:375-82.

48.

Grover

Lowensteyn

Joseph

et al . Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial. Arch Intern Med 2007;167:2296-303.

49.

Benner

Erhardt

Flammer

et al . A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile. Int J Clin Pract 2008;62:1484-98.

50.

D’Agostino

Vasan

Pencina

et al . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2007;117:743-53.

51.

Soureti

Hurling

Murray

et al . Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. J Cardiovasc Prev Rehabil 2010;17:519-23.

52.

Grover

Lowensteyn

Joseph

et al . Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy. Arch Intern Med 2007;167:2296-30.

53.

Teo

Ounpuu

Hawken

et al . Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647-58.

54.

Saba

Diep

Saini

Dhippayom

. Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. J Clin Pharm Ther 2014;39:240-7.

55.

Stead

Hartmann-Boyce

Perera

Lancaster

. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2013;(8):CD002850.

56.

Cahill

Lancaster

. Workplace interventions for smoking cessation. Cochrane Database Syst Rev 2014;(4): CD003440.

57.

Abegaz

Shehab

Gebreyohannes

et al . Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine Open 2017;96(4):e5641-9.

58.

Chockalingam

Bacher

Campbell

et al . Adherence to management of high blood pressure: recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Public Health 1998;89(Suppl 2):15-6.

59.

Fodor

Cutler

Irvine

et al . Adherence to non-pharmacological therapy for hypertension: problems and solutions. Can J Public Health 1998;89(Suppl 2):112-5.

60.

Vrijens

Vincze

Kristanto

Urquhart

Burnier

. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336(7653):1114-7.

61.

Faulkner

Wadibia

Lucas

Hilleman

. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy 2000;20:410-6.

62.

Marra

Johnston

Santschi

et al . Cost-effectiveness of pharmacist care for managing hypertension in Canada. Can Pharm J (Ott) 2017;150(3):184-97.